Факторы риска снижения фертильности у пациенток с врожденной дисфункцией коры надпочечников

При анализе публикаций, посвященных снижению фертильности пациенток с врожденной дисфункцией коры надпочечников, акцентируется внимание на снижении эстрогенизации. Проанализированы данные о течении полового созревания, исходах феминизирующей пластики у девочек с данным заболеванием в зависимости от степени компенсации и сроков начала лечения.

врожденная дисфункция коры надпочечников, пубертат, фертильность, эстрогенизация, компенсация

1. DeCrecchio L. Sopra un caso di apparenzi virili in unadonna. Morgagni 1865; 7: 154-188.

2. Steiger M., Reichstein T. Desoxycorticosterone (21-oxyprogesterone aust-3-oxy-atio cholensaure). Helv Chim Acta 1937; 20: 1164-1179.

3. Kendall E., Mason H., McKenzie B., Myers C.S., Koelsche G. Isolation in crystalline form of the hormone essential to life from the suprarenal cortex: Its chemical nature and physiologic properties. Trans Ass Am Phys 1934; 49: 147-152.

4. Wilkins L., Lewis R.A., Klein R., Rosemberg E. The suppression of androgen secretion by cortisone in a case of congenital adrenal hyperplasia. Bull Johns Hopkins Hosp 1950; 86: 249-252.

5. Bartter F.C., Forbes A.P., Leaf A. Congenital adrenal hyperplasia associated with the adrenogenital syndrome: an attempt to correct its disordered hormonal pattern. J Clin Invest 1950; 29: 797.

6. Cooper D.Y., Levin S., Narasimhulu S., Rosenthal O. Photochemical action spectrum of the terminal oxidase of mixed function oxidase systems. Science 1965; 147: 400-402.

7. Miller W.L. Molecular biology of steroid hormone synthesis. Endocrinol Rev 1988; 9: 295-318.

8. Mulaikal R.M., Migeon C.J., Rock J.A. Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. New Eng J Med 1987; 316: 4: 178-182.

9. Jaaskelainen J., Hippelainen M., Kiekara O., Voutilainen R. Child rate, pregnancy outcome and ovarian function in females with classical 21-hydroxylase deficiency. Acta Obstet Gynecol Scand 2000; 79: 8: 687-692.

10. Lo J.C., Grumbach M.M. Pregnancy outcomes in women with congenital virilizing adrenal hyperplasia. Endocrinol Metabol Clin North Am 2001; 30: 1: 207-229.

11. Krone N., Wachter I., Stefanidou M., Roscher A.A., Schwarz H.P. Mothers with congenital adrenal hyperplasia and their children: outcome of pregnancy, birth and childhood. Clin Endocrinol 2001; 55: 4: 523-529.

12. Stikkelbroeck N.M.M.L., Hermus A.R.M.M., Braat D.D.M., Otten B.J. Fertility in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Obstet Gynecol Surv 2003; 58: 4: 275-284.

13. Gastaud F., Bouvattier C., Duranteau L., Brauner R., Thibaud E., Kutten F., Bougneres P. Impaired sexual and reproductive outcomes in women with classical forms of congenital adrenal hyperplasia. J Clin Endocrinol Metabol 2007; 92: 4: 1391-1396.

14. Hagenfeldt K., Janson P.O., Holmdahl G., Falhammar H., Filipsson H., Frisen L., Thoren M., Nordenskjold A. Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod 2008; 23: 7: 1607-1613.

15. Conway G.S., Casteras A., De Silva P., Rumsby G. Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate. Clin Endocrinol 2009; 70: 6: 833-837.

16. Speiser P.W., White P.C. Congenital adrenal hyperplasia. New Eng J Med 2003; 349: 776-788.

17. Merke D.P., Bornstein S.R., Avila N.A., Chrousos G.P. NIH conference. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Int Med 2002; 136: 320-334.

18. Merke D.P., Cutler G.B. Jr. New ideas for medical treatment of congenital adrenal hyperplasia. Endocrinol Metabol Clin North Am 2001; 30: 121-135.

19. White P.C., Speiser P.W. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrin Rev 2000; 21: 245-291.

20. Newfield R.S., New M.I. 21-Hydroxylase deficiency. Ann New York Acad Sci 1997; 816: 219-229.

21. Goto M., Piper Hanley K., Marcos J. In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development. J Clin Inv 2006; 116: 953-960.

22. Prader A., Gurtner H.P. The syndrome of male pseudohermaphrodism in congenital adrenocortical hyperplasia without overproduction of androgens (adrenal male pseudohermaphrodism). Helv Paediat Acta 1955; 10: 397-412.

23. Riddick D.H., Hammond C.B. Adrenal virilism due to 21-hydroxylase deficiency in the postmenarchial female. Obstet Gynecol 1975; 45: 21-24.

24. Faglia G., Travaglini P., Neri V., Farrari C., Gattinoni L., Acerbi L. Occurrence of a virilizing syndrome with 21-hydroxylase deficiency after pregnancy. J Clin Endocrinol Metabol 1969; 29: 1325-1329.

25. Southren A.L., Saito A., Laufer A., Soffer L.F. Urinary hormone studies in untreated congenital adrenal hyperplasia during and after pregnancy. J Clin Endocrinol Metabol 1961; 21: 675.

26. Leichter S.B., Jacobs L.S. Normal gestation and diminished androgen responsiveness in an untreated patient with 21-hydroxylase deficiency. J Clin Endocrinol Metabol 1976; 42: 575-582.

27. Jones H., Verkauf B. Congenital adrenal hyperplasia: age at menarche and related events at puberty. Am J Obstet Gynecol 1971; 109: 292.

28. Ghali I., David M., David L. Linear growth and pubertal development in treated congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxford) 1977; 6: 425-436.

29. Trinh L., Nimkarn S., New M.I., Lin-Su K. Growth and pubertal characteristics in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Pediatr Endocrinol Metabol 2007; 20: 883-891.

30. Manoli I., Kanaka-Gantenbein Ch., Voutetakis A., Maniati-Christidi M., Dacou-Voutetakis C. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome. Clin Endocrinol 2002; 57: 669-676.

31. Klingensmith G., Garcia S., Jones H. Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effects on height, sexual maturation, and fertility. J Pediatr 1977; 90: 996-1004.

32. Hoimes-Walker D.J., Conway G.S., Honour J.W., Rumsby G., Jacobs H.S. Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol 1995; 43: 291-296.

33. Kulshreshtha B., Eunice M., Ammini A.C. Pubertal development among girls with classical congenital adrenal hyperplasia initiated on treatment at different ages. Ind J Endocrinol Metabol 2012; 16: 599-603.

34. Goy R.W., Uno H., Sholl S.A. Psychological and anatomical consequences of prenatal exposure to androgens in female rhesus. In: Toxicity of Hormones in Perinatal. Eds. T. Mori, H. Nagasawa. Life 1989; 127-142.

35. Johannsen T.H., Ripa C.P.L., Carlsen E., Starup J., Nielsen O.H., Schwartz M., Drzewiecki K.T., Mortensen E.L., Main K.M. Long-term gynecological outcomes in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Int J Pediatric Endocrinol 2010; 127-133.

36. Salardy S., Orsini L.F., Cacciari E., Partesotti S. Pelvic ultrasoundgraphy in girls with precocious puberty, congenital hyperplasia, obesity, or hirsutism. J Pediatr 1988; 112: 6: 880-887.

37. Charmandari E., Brook C.G.D., Hindmarsh P.C. Classic congenital adrenal hyperplasia and puberty. Eur J Endocrinol 2004; 151: 77-82.

38. Charmandari E., Hindmarsh P.C., Johnston A., Brook C.G. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. J Clin Endocrinol Metabol 2001; 86: 2701-2708.

39. Low S.C., Chapman K.E., Edwards C., Wells T., Robinson I.C., Seckl J.R. Sexual dimorphism of hepatic 11Β-hydroxysteroid dehydrogenase in the rat: the role of growth hormone patterns. J Endocrinol 1994; 143: 541-548.

40. Gelding S.V., Taylor N.F., Wood P.J., Noonan K., Weaver J.U., Wood D.F., Monson J.P. The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11Β-hydroxysteroid dehydrogenase activity. Clin Endocrinol (Oxford) 1998; 48: 153-162.

41. Moore J.S., Monson J.P., Kaltsas G., Putignano P., Wood P.J., Sheppard M.C., Besser G.M., Taylor N.F., Stewart P.M. Modulation of 11Β-hydroxysteroid dehydrogenase isozymes by growth hormoneand insulin-like growth factor: in vivo and in vitro studies. J Clin Endocrinol Metabol 1999; 84: 4172-4177.

42. Toogood A.A., Taylor N.F., Shalet S.M., Monson J.P. Modulation of cortisol metabolism by low-dose growth hormone replacement in elderly hypopituitary patients. J Clin Endocrinol Metabol 2000; 85: 1727-1730.

43. Miller J.D., Tannenbaum G.S., Colle E., Guyda H.J. Daytime pulsatile growth hormone secretion during childhood and adolescence. J Clin Endocrinol Metabol 1982; 55: 989-994.

44. Blum W.F., Albertson-Wikland K., Rosberg S., Ranke M.B. Serum levels of insulin-like growth factor-I (IGF-I) and IGF binding protein-3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metabol 1993; 76: 1610-1616.

45. Cutfield W.S., Bergman A.N., Menon R.K., Sperling M.A. The modified minimal model application to measurement of insulin sensitivity in children. J Clin Endocrinol Metabol 1990; 70: 1644-1650.

46. Mesiano S., Katz S.L., Lee J.Y., Jaffe R.B. Insulin-like growth factors augment steroid production and expression of steroidogenic enzymes in human fetal adrenal cortical cells: implications for adrenal androgen regulation. J Clin Endocrinol Metabol 1997; 82: 1390-1396.

47. Moghetti P., Castello R., Negri C., Tosi F., Spiazzi G.G., Brun E., Balducci R., Toscano V., Muggeo M. Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metabol 1996; 81: 881-886.

48. Nestler J.E., Jakubowicz D.J., de Vargas A.F., Brik C., Quintero N., Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metabol 1998; 83: 2001-2005.

49. Passerini-Glazel G. A new 1-stage procedure for clitorovaginoplasty in severely masculinized female pseudohermaphrodites. J Urol 1989; 142: 565-568.

50. Gonzalez R., Fernandez E.T. Single-stage feminization genitoplasty. J Urol 1990; 143: 776-778.

51. Alizai N.K., Thomas D.F., Lilford R.J., Batchelor A.G., Johnson N. Feminizing genitoplasty for congenital adrenal hyperplasia: what happens at puberty? J Urol 1999; 161: 1588-1591.

52. Bailez M.M., Gearhart J.P., Migeon C., Rock J. Vaginal reconstruction after initial construction of the external genitalia in girls with salt-wasting adrenal hyperplasia. J Urol 1992; 148: 680-684.

53. Creighton S.M. Long-term outcome of feminization surgery: the London experience. BJU Int 2004; 93: 3: 44-46.

54. Duckett J.W., Baskin L.S. Genitoplasty for intersex anomalies. Eur J Pediatr 1993; 152: 80-84.

55. Kogan S.J. Feminizing genital reconstruction for male pseudohermaphroditism. Eur J Pediatr 1993; 152: 85-87.

56. Фомина М.А., Бижанова Д.А., Арзамасцева Л.В., Протасов А.А., Карманов М.Е., Дядик Т.Г. Оценка результатов феминизирующей пластики у девочек-подростков с врожденной дисфункцией коры надпочечников в отдаленном послеоперационном периоде. Детская больница 2010; 2: 35-39.

57. Escala J.M., Cadena Y., Lopez P-.J., Angel L., Retamal M.G., Letelier N., Zubieta R. Feminizing genitoplasty in adrenal congenital hyperplasia: one or two surgical steps? Arch Esp Urol 2009; 62: 9: 724-730.

58. Krege S., Walz K.H., Hauffa B.P., Korner I., Rubben H. Long-term follow-up of female patients with congenital adrenal hyperplasia from 21-hydroxylase deficiency, with special emphasis on the results of vaginoplasty. BJU Int 2000; 86: 253-259.

59. Merlo S., Frasca G., Canonico P.L., Sortino M.A. Differential involvement of estrogen receptor alpha and estrogen receptor beta in the healing promoting effect of estrogen in human keratinocytes. J Endocrinol 2009; 200: 189-197.

60. Florian M., Lu Y., Angle M., Magder S. Estrogen induced changes in Akt-dependent activation of endothelial nitric oxide synthase and vasodilation. Steroids 2004; 69: 637-645.

61. Ashcroft G.S., Ashworth J.J. Potential role of estrogens in wound healing. Am J Clin Dermatol 2003; 4: 737-743.

62. Pirila E., Ramamurthy N., Maisi P., McClain S., Kucine A., Wahlgren J. Wound healing in ovariectomized rats: effects of chemically modified tetracycline (CMT-8) and estrogen on matrix metalloproteinases-8, -13 and type I collagen expression. Curr Med Chem 2001; 8: 281-294.

63. Claahsen-van der Grinten H.L., Stikkelbroeck N.M.M.L., Sweep C.G.J., Hermus A.R.M.M., Otten B.J. Fertility in patients with congenital adrenal hyperplasia. J Pediatr Endocrinol Metabol 2006; 19: 5: 677-685.

64. Dumic M., Janjanin N., Ille J. Pregnancy outcomes in women with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Pediatr Endocrinol Metabol 2005; 18: 9: 887-895.

65. Crouch N.S., Minto C.L., Laio L.M., Woodhouse C.R., Creighton S.M. Genital sensation after feminizing genitoplasty for congenital adrenal hyperplasia: apilot study. BJU Int 2004; 93: 135-138.

66. Meyer-Bahlburg H.F.L. What causes low rates of childbearing in congenital adrenal hyperplasia? J Clin Endocrinol Metabol 1999; 84: 6: 1844-1847.

67. Hoepffner W., Schulze E., Bennek J., Keller E., Willgerodt H. Pregnancies in patients with congenital adrenal hyperplasia with complete or almost complete impairment of 21-hydroxylase activity. Fertil Steril 2004; 81: 5: 1314-1321.

68. Kulshreshtha B., Marumudi E., Khurana M.L., Kriplani A., Kinra G., Gupta D.K., Kucheria K., Khadgawat R., Gupta N., Seith A., Ammini A.C. Fertility among women with classical congenital adrenal hyperplasia: report of seven cases where treatment was started after 9 years of age. Gynecol Endocrinol 2008; 24: 5: 267-272.